Journal of Nephrology & Therapeutics

Elizabeth Jarvis

Publications

• Research Article
  The Slo-Niacin Trial: A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of Extended Release Niacin for Phosphate Lowering in Haemodialysis Patients
  Author(s): Ken-Soon Tan, Deepak L Vardesh, Padma Raman, Jeremy Frazier and Elizabeth JarvisKen-Soon Tan, Deepak L Vardesh, Padma Raman, Jeremy Frazier and Elizabeth Jarvis
  
  Aim: Is once daily low dose extended release niacin effective at lowering phosphate? Background: Serum phosphate levels correlate with mortality in dialysis patients. Current phosphate binders often cause side-effects leading to poor compliance. Niacin has previously been shown to lower serum phosphate in patients with kidney disease. However, at doses previously used (≥ 1 g daily), it is poorly tolerated. Slo-niacin® is a extended release formulation taken once daily. Methods: The study was a single-centre double-blind placebo-controlled randomised cross-over trial in haemodialysis patients. All patients received both active treatment (500 mg Slo-niacin® daily) and matching placebo for 8 weeks each with intervening 2 week.. Read More»
  DOI: 10.4172/2161-0959.1000157

  Abstract PDF